Lung Adenocarcinoma

Lung adenocarcinoma is the most common type of non-small cell lung cancer. It begins in the glandular cells that line the smaller airways and air sacs, usually in the outer parts of the lung. It can occur in people who never smoked and in people exposed to asbestos, radon, diesel exhaust, or secondhand smoke.

Origin

The word combines the Greek adeno- (gland) with carcinoma (a malignant tumor of epithelial origin, from Greek karkinos, crab). The term came into wide medical use in the late 19th and early 20th centuries as pathologists began classifying lung cancers by the type of tissue they resembled under the microscope.

Significance in Asbestos Context

Asbestos exposure is a recognized cause of lung cancer, including the adenocarcinoma subtype. Under the Helsinki Criteria, an asbestos-related lung cancer can be established when there is documented exposure plus either a sufficient latency period (typically 10+ years), evidence of asbestosis, markers of high cumulative exposure (such as elevated fiber counts or pleural plaques), or a well-documented occupational exposure history. The specific cell type, adenocarcinoma versus squamous or small cell, doesn't change whether asbestos is considered a cause; what matters is the exposure history and the medical evidence linking it to the tumor. Patients should make sure their medical records clearly state the histologic subtype, any imaging findings of pleural plaques or asbestosis, and a complete occupational history, because these are the elements that connect the diagnosis to an asbestos claim.

Example Sentence

After his CT scan revealed a peripheral lung nodule, the biopsy confirmed lung adenocarcinoma, and his pulmonologist asked detailed questions about his decades working as a pipefitter in shipyards.

Related Terms

Non-Small Cell Lung Cancer, Helsinki Criteria, Pleural Plaques, Asbestosis, Bronchogenic Carcinoma, Latency Period

Notes

• Ask your pathologist for a copy of the biopsy report listing the specific histologic subtype (adenocarcinoma) and any molecular testing results (EGFR, ALK, ROS1, KRAS, PD-L1). These guide treatment and may be relevant to your case.
• Request that your radiology reports specifically note any pleural plaques, pleural thickening, or signs of asbestosis, since these findings support an asbestos link.
• Preserve a written occupational and exposure history including job titles, employers, dates, and any known asbestos products. Give this to both your treating physicians and your legal team.
• If you smoked, the asbestos link is still valid; asbestos and tobacco act together to multiply lung cancer risk, and this synergy is well established in medical literature.
• Ask whether you qualify for targeted therapy or immunotherapy based on molecular testing, as treatment options for adenocarcinoma have expanded significantly.